nodes	percent_of_prediction	percent_of_DWPC	metapath
Framycetin—Acarbose—type 2 diabetes mellitus	0.571	1	CrCtD
Framycetin—Neomycin—Acarbose—type 2 diabetes mellitus	0.098	0.288	CrCrCtD
Framycetin—Paromomycin—Acarbose—type 2 diabetes mellitus	0.0881	0.259	CrCrCtD
Framycetin—Amikacin—Acarbose—type 2 diabetes mellitus	0.0802	0.236	CrCrCtD
Framycetin—Kanamycin—Acarbose—type 2 diabetes mellitus	0.0737	0.217	CrCrCtD
Framycetin—CXCR4—endothelium—type 2 diabetes mellitus	0.00431	0.234	CbGeAlD
Framycetin—CXCR4—islet of Langerhans—type 2 diabetes mellitus	0.00245	0.133	CbGeAlD
Framycetin—CXCR4—retina—type 2 diabetes mellitus	0.0021	0.114	CbGeAlD
Framycetin—CXCR4—cardiovascular system—type 2 diabetes mellitus	0.00177	0.0962	CbGeAlD
Framycetin—CXCR4—kidney—type 2 diabetes mellitus	0.00174	0.0941	CbGeAlD
Framycetin—CXCR4—pancreas—type 2 diabetes mellitus	0.00172	0.0935	CbGeAlD
Framycetin—CXCR4—cortex of kidney—type 2 diabetes mellitus	0.00169	0.0916	CbGeAlD
Framycetin—CXCR4—adipose tissue—type 2 diabetes mellitus	0.00156	0.0848	CbGeAlD
Framycetin—CXCR4—liver—type 2 diabetes mellitus	0.0011	0.0595	CbGeAlD
Framycetin—Glaucoma—Gliclazide—type 2 diabetes mellitus	0.000694	0.0263	CcSEcCtD
Framycetin—Viral infection—Gliclazide—type 2 diabetes mellitus	0.000578	0.0219	CcSEcCtD
Framycetin—Erythema—Tolbutamide—type 2 diabetes mellitus	0.000548	0.0208	CcSEcCtD
Framycetin—Viral infection—Valsartan—type 2 diabetes mellitus	0.000531	0.0202	CcSEcCtD
Framycetin—Erythema—Tolazamide—type 2 diabetes mellitus	0.000498	0.0189	CcSEcCtD
Framycetin—Erythema—Acarbose—type 2 diabetes mellitus	0.000479	0.0181	CcSEcCtD
Framycetin—Anaphylactic shock—Linagliptin—type 2 diabetes mellitus	0.000402	0.0153	CcSEcCtD
Framycetin—Infection—Linagliptin—type 2 diabetes mellitus	0.0004	0.0152	CcSEcCtD
Framycetin—Erythema—Repaglinide—type 2 diabetes mellitus	0.0004	0.0151	CcSEcCtD
Framycetin—Swelling—Valsartan—type 2 diabetes mellitus	0.000395	0.015	CcSEcCtD
Framycetin—Diarrhoea—Miglitol—type 2 diabetes mellitus	0.00034	0.0129	CcSEcCtD
Framycetin—Swelling—Irbesartan—type 2 diabetes mellitus	0.000339	0.0129	CcSEcCtD
Framycetin—Erythema—Glipizide—type 2 diabetes mellitus	0.000331	0.0125	CcSEcCtD
Framycetin—Anaphylactic shock—Repaglinide—type 2 diabetes mellitus	0.000326	0.0124	CcSEcCtD
Framycetin—Swelling—Losartan—type 2 diabetes mellitus	0.000319	0.0121	CcSEcCtD
Framycetin—Pruritus—Tolbutamide—type 2 diabetes mellitus	0.000316	0.012	CcSEcCtD
Framycetin—Erythema—Glimepiride—type 2 diabetes mellitus	0.000308	0.0117	CcSEcCtD
Framycetin—Anaphylactic shock—Rosiglitazone—type 2 diabetes mellitus	0.000308	0.0117	CcSEcCtD
Framycetin—Infection—Rosiglitazone—type 2 diabetes mellitus	0.000306	0.0116	CcSEcCtD
Framycetin—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.000296	0.0112	CcSEcCtD
Framycetin—Nausea—Miglitol—type 2 diabetes mellitus	0.000295	0.0112	CcSEcCtD
Framycetin—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.000288	0.0109	CcSEcCtD
Framycetin—Pruritus—Tolazamide—type 2 diabetes mellitus	0.000288	0.0109	CcSEcCtD
Framycetin—Pruritus—Chlorpropamide—type 2 diabetes mellitus	0.000288	0.0109	CcSEcCtD
Framycetin—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.000278	0.0105	CcSEcCtD
Framycetin—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.000278	0.0105	CcSEcCtD
Framycetin—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.000275	0.0104	CcSEcCtD
Framycetin—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.000267	0.0101	CcSEcCtD
Framycetin—Pruritus—Nateglinide—type 2 diabetes mellitus	0.000267	0.0101	CcSEcCtD
Framycetin—Nausea—Tolbutamide—type 2 diabetes mellitus	0.000265	0.0101	CcSEcCtD
Framycetin—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.000259	0.0098	CcSEcCtD
Framycetin—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	0.000258	0.0098	CcSEcCtD
Framycetin—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.000258	0.00977	CcSEcCtD
Framycetin—Infection—Pioglitazone—type 2 diabetes mellitus	0.000257	0.00973	CcSEcCtD
Framycetin—Erythema—Glyburide—type 2 diabetes mellitus	0.000254	0.00964	CcSEcCtD
Framycetin—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.000252	0.00954	CcSEcCtD
Framycetin—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.000251	0.00951	CcSEcCtD
Framycetin—Infection—Sitagliptin—type 2 diabetes mellitus	0.000249	0.00945	CcSEcCtD
Framycetin—Vomiting—Acarbose—type 2 diabetes mellitus	0.000248	0.00942	CcSEcCtD
Framycetin—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000242	0.00916	CcSEcCtD
Framycetin—Nausea—Tolazamide—type 2 diabetes mellitus	0.000242	0.00916	CcSEcCtD
Framycetin—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00024	0.00911	CcSEcCtD
Framycetin—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00024	0.00908	CcSEcCtD
Framycetin—Nausea—Acarbose—type 2 diabetes mellitus	0.000232	0.0088	CcSEcCtD
Framycetin—Pruritus—Repaglinide—type 2 diabetes mellitus	0.000231	0.00875	CcSEcCtD
Framycetin—Erythema—Gliclazide—type 2 diabetes mellitus	0.000228	0.00866	CcSEcCtD
Framycetin—Infection—Bromocriptine—type 2 diabetes mellitus	0.000226	0.00855	CcSEcCtD
Framycetin—Nausea—Nateglinide—type 2 diabetes mellitus	0.000224	0.00848	CcSEcCtD
Framycetin—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000223	0.00846	CcSEcCtD
Framycetin—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.000218	0.00827	CcSEcCtD
Framycetin—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000211	0.00799	CcSEcCtD
Framycetin—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000207	0.00786	CcSEcCtD
Framycetin—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000199	0.00753	CcSEcCtD
Framycetin—Nausea—Repaglinide—type 2 diabetes mellitus	0.000194	0.00734	CcSEcCtD
Framycetin—Erythema—Metformin—type 2 diabetes mellitus	0.000191	0.00725	CcSEcCtD
Framycetin—Pruritus—Glipizide—type 2 diabetes mellitus	0.000191	0.00724	CcSEcCtD
Framycetin—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00019	0.00722	CcSEcCtD
Framycetin—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000185	0.00703	CcSEcCtD
Framycetin—Infection—Gliclazide—type 2 diabetes mellitus	0.000185	0.00702	CcSEcCtD
Framycetin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000185	0.00701	CcSEcCtD
Framycetin—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000185	0.007	CcSEcCtD
Framycetin—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000183	0.00694	CcSEcCtD
Framycetin—Erythema—Irbesartan—type 2 diabetes mellitus	0.00018	0.00684	CcSEcCtD
Framycetin—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000178	0.00675	CcSEcCtD
Framycetin—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000177	0.0067	CcSEcCtD
Framycetin—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000172	0.00653	CcSEcCtD
Framycetin—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000172	0.00651	CcSEcCtD
Framycetin—Vomiting—Glipizide—type 2 diabetes mellitus	0.000172	0.0065	CcSEcCtD
Framycetin—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000171	0.00649	CcSEcCtD
Framycetin—Infection—Valsartan—type 2 diabetes mellitus	0.00017	0.00645	CcSEcCtD
Framycetin—Erythema—Losartan—type 2 diabetes mellitus	0.00017	0.00643	CcSEcCtD
Framycetin—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000169	0.00642	CcSEcCtD
Framycetin—Infection—Orlistat—type 2 diabetes mellitus	0.000168	0.00637	CcSEcCtD
Framycetin—Nausea—Glipizide—type 2 diabetes mellitus	0.00016	0.00607	CcSEcCtD
Framycetin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00016	0.00607	CcSEcCtD
Framycetin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00016	0.00605	CcSEcCtD
Framycetin—CXCR4—Peptide ligand-binding receptors—EDN1—type 2 diabetes mellitus	0.000159	0.0036	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDNRB—type 2 diabetes mellitus	0.000157	0.00355	CbGpPWpGaD
Framycetin—CXCR4—Disease—VPS26A—type 2 diabetes mellitus	0.000155	0.00351	CbGpPWpGaD
Framycetin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000155	0.00589	CcSEcCtD
Framycetin—Infection—Metformin—type 2 diabetes mellitus	0.000155	0.00587	CcSEcCtD
Framycetin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000153	0.0058	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—HTR2C—type 2 diabetes mellitus	0.000153	0.00345	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—MMP9—type 2 diabetes mellitus	0.00015	0.00338	CbGpPWpGaD
Framycetin—Nausea—Glimepiride—type 2 diabetes mellitus	0.00015	0.00567	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—MTNR1B—type 2 diabetes mellitus	0.000149	0.00337	CbGpPWpGaD
Framycetin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000149	0.00565	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDNRA—type 2 diabetes mellitus	0.000148	0.00335	CbGpPWpGaD
Framycetin—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000147	0.00558	CcSEcCtD
Framycetin—Pruritus—Glyburide—type 2 diabetes mellitus	0.000147	0.00557	CcSEcCtD
Framycetin—Infection—Irbesartan—type 2 diabetes mellitus	0.000146	0.00554	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—MTNR1A—type 2 diabetes mellitus	0.000146	0.00329	CbGpPWpGaD
Framycetin—Erythema—Ramipril—type 2 diabetes mellitus	0.000146	0.00552	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—GLP1R—type 2 diabetes mellitus	0.000145	0.00328	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—ADRA2A—type 2 diabetes mellitus	0.000145	0.00328	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—GHRL—type 2 diabetes mellitus	0.000145	0.00327	CbGpPWpGaD
Framycetin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000144	0.00547	CcSEcCtD
Framycetin—CXCR4—G alpha (i) signalling events—GNB3—type 2 diabetes mellitus	0.000143	0.00324	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CCKAR—type 2 diabetes mellitus	0.000143	0.00323	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCR5—type 2 diabetes mellitus	0.000143	0.00322	CbGpPWpGaD
Framycetin—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000142	0.00539	CcSEcCtD
Framycetin—CXCR4—Peptide ligand-binding receptors—C3—type 2 diabetes mellitus	0.000139	0.00315	CbGpPWpGaD
Framycetin—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000139	0.00525	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—GCGR—type 2 diabetes mellitus	0.000138	0.00313	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—SRC—type 2 diabetes mellitus	0.000138	0.00312	CbGpPWpGaD
Framycetin—Infection—Losartan—type 2 diabetes mellitus	0.000138	0.00522	CcSEcCtD
Framycetin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000137	0.00521	CcSEcCtD
Framycetin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000135	0.00511	CcSEcCtD
Framycetin—CXCR4—Peptide ligand-binding receptors—AGT—type 2 diabetes mellitus	0.000132	0.00299	CbGpPWpGaD
Framycetin—Vomiting—Glyburide—type 2 diabetes mellitus	0.000132	0.005	CcSEcCtD
Framycetin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000132	0.005	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—IAPP—type 2 diabetes mellitus	0.000129	0.00291	CbGpPWpGaD
Framycetin—CXCR4—HIV Infection—CCR5—type 2 diabetes mellitus	0.000129	0.00291	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—ADCY5—type 2 diabetes mellitus	0.000128	0.00289	CbGpPWpGaD
Framycetin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000128	0.00484	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—GIPR—type 2 diabetes mellitus	0.000127	0.00288	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—GRK5—type 2 diabetes mellitus	0.000127	0.00288	CbGpPWpGaD
Framycetin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000126	0.00478	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—GCGR—type 2 diabetes mellitus	0.000126	0.00284	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—AGTR2—type 2 diabetes mellitus	0.000125	0.00282	CbGpPWpGaD
Framycetin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000125	0.00473	CcSEcCtD
Framycetin—Nausea—Glyburide—type 2 diabetes mellitus	0.000123	0.00468	CcSEcCtD
Framycetin—Pruritus—Valsartan—type 2 diabetes mellitus	0.000121	0.00459	CcSEcCtD
Framycetin—CXCR4—G alpha (i) signalling events—CCR5—type 2 diabetes mellitus	0.00012	0.00272	CbGpPWpGaD
Framycetin—Pruritus—Orlistat—type 2 diabetes mellitus	0.00012	0.00454	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—EDNRB—type 2 diabetes mellitus	0.00012	0.0027	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—ARAP1—type 2 diabetes mellitus	0.000119	0.00269	CbGpPWpGaD
Framycetin—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000119	0.0045	CcSEcCtD
Framycetin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000119	0.00449	CcSEcCtD
Framycetin—CXCR4—G alpha (i) signalling events—C3—type 2 diabetes mellitus	0.000117	0.00265	CbGpPWpGaD
Framycetin—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000117	0.00444	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—MC4R—type 2 diabetes mellitus	0.000117	0.00263	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—HTR2C—type 2 diabetes mellitus	0.000116	0.00262	CbGpPWpGaD
Framycetin—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000116	0.00439	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—GIPR—type 2 diabetes mellitus	0.000116	0.00261	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GRK5—type 2 diabetes mellitus	0.000116	0.00261	CbGpPWpGaD
Framycetin—CXCR4—Disease—SLC5A4—type 2 diabetes mellitus	0.000113	0.00256	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—EDNRA—type 2 diabetes mellitus	0.000113	0.00255	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—AVP—type 2 diabetes mellitus	0.000112	0.00254	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—GIP—type 2 diabetes mellitus	0.000112	0.00253	CbGpPWpGaD
Framycetin—CXCR4—G alpha (i) signalling events—AGT—type 2 diabetes mellitus	0.000112	0.00252	CbGpPWpGaD
Framycetin—CXCR4—GPCRs, Class A Rhodopsin-like—CCR5—type 2 diabetes mellitus	0.000112	0.00252	CbGpPWpGaD
Framycetin—Nausea—Gliclazide—type 2 diabetes mellitus	0.000111	0.0042	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—ADRA2A—type 2 diabetes mellitus	0.000111	0.0025	CbGpPWpGaD
Framycetin—Pruritus—Metformin—type 2 diabetes mellitus	0.00011	0.00418	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—GHRL—type 2 diabetes mellitus	0.00011	0.00249	CbGpPWpGaD
Framycetin—CXCR4—Disease—PPP1R3C—type 2 diabetes mellitus	0.000109	0.00247	CbGpPWpGaD
Framycetin—CXCR4—Disease—ENPP1—type 2 diabetes mellitus	0.000109	0.00247	CbGpPWpGaD
Framycetin—CXCR4—Disease—G6PC—type 2 diabetes mellitus	0.000109	0.00247	CbGpPWpGaD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCL2—type 2 diabetes mellitus	0.000109	0.00246	CbGpPWpGaD
Framycetin—Vomiting—Valsartan—type 2 diabetes mellitus	0.000109	0.00413	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—VPS26A—type 2 diabetes mellitus	0.000109	0.00246	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CALCA—type 2 diabetes mellitus	0.000109	0.00246	CbGpPWpGaD
Framycetin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000108	0.00411	CcSEcCtD
Framycetin—Vomiting—Orlistat—type 2 diabetes mellitus	0.000108	0.00408	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDN1—type 2 diabetes mellitus	0.000107	0.00242	CbGpPWpGaD
Framycetin—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000107	0.00405	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—MC4R—type 2 diabetes mellitus	0.000106	0.00239	CbGpPWpGaD
Framycetin—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000104	0.00395	CcSEcCtD
Framycetin—CXCR4—HIF-1-alpha transcription factor network—AKT1—type 2 diabetes mellitus	0.000104	0.00235	CbGpPWpGaD
Framycetin—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000102	0.00387	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—GIP—type 2 diabetes mellitus	0.000102	0.0023	CbGpPWpGaD
Framycetin—Nausea—Valsartan—type 2 diabetes mellitus	0.000102	0.00386	CcSEcCtD
Framycetin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000101	0.00382	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—GCG—type 2 diabetes mellitus	0.000101	0.00228	CbGpPWpGaD
Framycetin—Nausea—Orlistat—type 2 diabetes mellitus	0.000101	0.00381	CcSEcCtD
Framycetin—Vomiting—Metformin—type 2 diabetes mellitus	9.92e-05	0.00376	CcSEcCtD
Framycetin—Pruritus—Losartan—type 2 diabetes mellitus	9.8e-05	0.00372	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	9.56e-05	0.00216	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	9.54e-05	0.00215	CbGpPWpGaD
Framycetin—Diarrhoea—Losartan—type 2 diabetes mellitus	9.48e-05	0.00359	CcSEcCtD
Framycetin—Vomiting—Irbesartan—type 2 diabetes mellitus	9.36e-05	0.00355	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	9.34e-05	0.00211	CbGpPWpGaD
Framycetin—CXCR4—Disease—ACACA—type 2 diabetes mellitus	9.31e-05	0.0021	CbGpPWpGaD
Framycetin—Nausea—Metformin—type 2 diabetes mellitus	9.26e-05	0.00351	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	9.21e-05	0.00208	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	8.88e-05	0.00201	CbGpPWpGaD
Framycetin—Vomiting—Losartan—type 2 diabetes mellitus	8.81e-05	0.00334	CcSEcCtD
Framycetin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	8.75e-05	0.00332	CcSEcCtD
Framycetin—Nausea—Irbesartan—type 2 diabetes mellitus	8.74e-05	0.00331	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—GNB3—type 2 diabetes mellitus	8.68e-05	0.00196	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	8.66e-05	0.00196	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	8.6e-05	0.00194	CbGpPWpGaD
Framycetin—CXCR4—Disease—SLC5A2—type 2 diabetes mellitus	8.59e-05	0.00194	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—AKT1—type 2 diabetes mellitus	8.58e-05	0.00194	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—AVP—type 2 diabetes mellitus	8.56e-05	0.00193	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	8.42e-05	0.0019	CbGpPWpGaD
Framycetin—Pruritus—Ramipril—type 2 diabetes mellitus	8.4e-05	0.00319	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	8.36e-05	0.00189	CbGpPWpGaD
Framycetin—Nausea—Losartan—type 2 diabetes mellitus	8.23e-05	0.00312	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	8.21e-05	0.00185	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—EDN1—type 2 diabetes mellitus	8.14e-05	0.00184	CbGpPWpGaD
Framycetin—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.13e-05	0.00308	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	8.08e-05	0.00182	CbGpPWpGaD
Framycetin—CXCR4—Disease—PCK1—type 2 diabetes mellitus	7.8e-05	0.00176	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	7.65e-05	0.00173	CbGpPWpGaD
Framycetin—CXCR4—Disease—TLE4—type 2 diabetes mellitus	7.59e-05	0.00171	CbGpPWpGaD
Framycetin—Vomiting—Ramipril—type 2 diabetes mellitus	7.55e-05	0.00286	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	7.46e-05	0.00168	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GCGR—type 2 diabetes mellitus	7.43e-05	0.00168	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	7.33e-05	0.00166	CbGpPWpGaD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	7.31e-05	0.00165	CbGpPWpGaD
Framycetin—CXCR4—Disease—HK1—type 2 diabetes mellitus	7.31e-05	0.00165	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CCR5—type 2 diabetes mellitus	7.28e-05	0.00164	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	7.27e-05	0.00164	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—C3—type 2 diabetes mellitus	7.11e-05	0.00161	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	7.1e-05	0.0016	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	7.06e-05	0.0016	CbGpPWpGaD
Framycetin—CXCR4—Disease—GCKR—type 2 diabetes mellitus	7.06e-05	0.00159	CbGpPWpGaD
Framycetin—Nausea—Ramipril—type 2 diabetes mellitus	7.06e-05	0.00267	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—GRK5—type 2 diabetes mellitus	6.83e-05	0.00154	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GIPR—type 2 diabetes mellitus	6.83e-05	0.00154	CbGpPWpGaD
Framycetin—CXCR4—Disease—ALDOB—type 2 diabetes mellitus	6.76e-05	0.00153	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	6.76e-05	0.00153	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—AGT—type 2 diabetes mellitus	6.76e-05	0.00153	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IAPP—type 2 diabetes mellitus	6.6e-05	0.00149	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	6.56e-05	0.00148	CbGpPWpGaD
Framycetin—CXCR4—Disease—SPRY2—type 2 diabetes mellitus	6.45e-05	0.00146	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	6.45e-05	0.00146	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	6.41e-05	0.00145	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	6.38e-05	0.00144	CbGpPWpGaD
Framycetin—CXCR4—Disease—RBP4—type 2 diabetes mellitus	6.29e-05	0.00142	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MC4R—type 2 diabetes mellitus	6.25e-05	0.00141	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	6.25e-05	0.00141	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	6.22e-05	0.00141	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	6.15e-05	0.00139	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	6.14e-05	0.00139	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GIP—type 2 diabetes mellitus	6.02e-05	0.00136	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	5.96e-05	0.00135	CbGpPWpGaD
Framycetin—CXCR4—Disease—SLC2A2—type 2 diabetes mellitus	5.87e-05	0.00133	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	5.8e-05	0.00131	CbGpPWpGaD
Framycetin—CXCR4—Disease—MTR—type 2 diabetes mellitus	5.75e-05	0.0013	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—LEPR—type 2 diabetes mellitus	5.72e-05	0.00129	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—GCG—type 2 diabetes mellitus	5.69e-05	0.00129	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	5.67e-05	0.00128	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GHRL—type 2 diabetes mellitus	5.65e-05	0.00128	CbGpPWpGaD
Framycetin—CXCR4—Disease—NAMPT—type 2 diabetes mellitus	5.64e-05	0.00127	CbGpPWpGaD
Framycetin—CXCR4—Disease—GCK—type 2 diabetes mellitus	5.61e-05	0.00127	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	5.6e-05	0.00126	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CALCA—type 2 diabetes mellitus	5.58e-05	0.00126	CbGpPWpGaD
Framycetin—CXCR4—Disease—IAPP—type 2 diabetes mellitus	5.57e-05	0.00126	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—CCL2—type 2 diabetes mellitus	5.57e-05	0.00126	CbGpPWpGaD
Framycetin—CXCR4—Disease—SLC9A1—type 2 diabetes mellitus	5.47e-05	0.00124	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	5.46e-05	0.00123	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TLE4—type 2 diabetes mellitus	5.31e-05	0.0012	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GCG—type 2 diabetes mellitus	5.17e-05	0.00117	CbGpPWpGaD
Framycetin—CXCR4—Disease—HMGA1—type 2 diabetes mellitus	5.13e-05	0.00116	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—ADRB3—type 2 diabetes mellitus	5.12e-05	0.00116	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	5.08e-05	0.00115	CbGpPWpGaD
Framycetin—CXCR4—Disease—PSMD6—type 2 diabetes mellitus	5.03e-05	0.00114	CbGpPWpGaD
Framycetin—CXCR4—Disease—SNAP25—type 2 diabetes mellitus	5.03e-05	0.00114	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CRHR1—type 2 diabetes mellitus	4.94e-05	0.00112	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	4.9e-05	0.00111	CbGpPWpGaD
Framycetin—CXCR4—Disease—CYBA—type 2 diabetes mellitus	4.87e-05	0.0011	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—AVP—type 2 diabetes mellitus	4.84e-05	0.00109	CbGpPWpGaD
Framycetin—CXCR4—Disease—CALCA—type 2 diabetes mellitus	4.71e-05	0.00106	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	4.6e-05	0.00104	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	4.56e-05	0.00103	CbGpPWpGaD
Framycetin—CXCR4—Disease—SLC2A1—type 2 diabetes mellitus	4.55e-05	0.00103	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	4.52e-05	0.00102	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SPRY2—type 2 diabetes mellitus	4.52e-05	0.00102	CbGpPWpGaD
Framycetin—CXCR4—Disease—NOS1—type 2 diabetes mellitus	4.48e-05	0.00101	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—GNB3—type 2 diabetes mellitus	4.45e-05	0.00101	CbGpPWpGaD
Framycetin—CXCR4—Disease—TCF7L2—type 2 diabetes mellitus	4.43e-05	0.001	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RBP4—type 2 diabetes mellitus	4.4e-05	0.000995	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GLP1R—type 2 diabetes mellitus	4.4e-05	0.000995	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—AVP—type 2 diabetes mellitus	4.39e-05	0.000993	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—MMP3—type 2 diabetes mellitus	4.39e-05	0.000993	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	4.37e-05	0.000988	CbGpPWpGaD
Framycetin—CXCR4—Disease—SLC2A4—type 2 diabetes mellitus	4.36e-05	0.000985	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCKAR—type 2 diabetes mellitus	4.33e-05	0.000979	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—EDN1—type 2 diabetes mellitus	4.18e-05	0.000944	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	4.11e-05	0.00093	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—C3—type 2 diabetes mellitus	4.02e-05	0.000908	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	3.97e-05	0.000897	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	3.93e-05	0.000887	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IAPP—type 2 diabetes mellitus	3.9e-05	0.000881	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—INSR—type 2 diabetes mellitus	3.88e-05	0.000876	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—AGT—type 2 diabetes mellitus	3.82e-05	0.000863	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TRPC6—type 2 diabetes mellitus	3.81e-05	0.000861	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	3.8e-05	0.00086	CbGpPWpGaD
Framycetin—CXCR4—Disease—TGFBR2—type 2 diabetes mellitus	3.79e-05	0.000857	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AGTR2—type 2 diabetes mellitus	3.79e-05	0.000856	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCR5—type 2 diabetes mellitus	3.74e-05	0.000844	CbGpPWpGaD
Framycetin—CXCR4—Disease—CDKN2B—type 2 diabetes mellitus	3.67e-05	0.00083	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—C3—type 2 diabetes mellitus	3.65e-05	0.000825	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EDNRB—type 2 diabetes mellitus	3.63e-05	0.000819	CbGpPWpGaD
Framycetin—CXCR4—Disease—APOB—type 2 diabetes mellitus	3.58e-05	0.000809	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	3.53e-05	0.000798	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HTR2C—type 2 diabetes mellitus	3.52e-05	0.000796	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PSMD6—type 2 diabetes mellitus	3.52e-05	0.000796	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—AGT—type 2 diabetes mellitus	3.47e-05	0.000784	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EDNRA—type 2 diabetes mellitus	3.42e-05	0.000774	CbGpPWpGaD
Framycetin—CXCR4—Disease—LPL—type 2 diabetes mellitus	3.42e-05	0.000773	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CALM1—type 2 diabetes mellitus	3.41e-05	0.000771	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CYBA—type 2 diabetes mellitus	3.41e-05	0.00077	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	3.35e-05	0.000757	CbGpPWpGaD
Framycetin—CXCR4—Disease—ADCY5—type 2 diabetes mellitus	3.35e-05	0.000757	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PLAT—type 2 diabetes mellitus	3.34e-05	0.000754	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GHRL—type 2 diabetes mellitus	3.34e-05	0.000754	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CALCA—type 2 diabetes mellitus	3.3e-05	0.000745	CbGpPWpGaD
Framycetin—CXCR4—Disease—PPP2CA—type 2 diabetes mellitus	3.21e-05	0.000725	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	3.21e-05	0.000724	CbGpPWpGaD
Framycetin—CXCR4—Disease—CCR5—type 2 diabetes mellitus	3.15e-05	0.000712	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	3.1e-05	0.000702	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	3.09e-05	0.000698	CbGpPWpGaD
Framycetin—CXCR4—Disease—MTHFR—type 2 diabetes mellitus	3.08e-05	0.000696	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GCG—type 2 diabetes mellitus	3.05e-05	0.00069	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PTPN1—type 2 diabetes mellitus	3.05e-05	0.00069	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	3e-05	0.000679	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	2.99e-05	0.000676	CbGpPWpGaD
Framycetin—CXCR4—Disease—HIF1A—type 2 diabetes mellitus	2.94e-05	0.000664	CbGpPWpGaD
Framycetin—CXCR4—Disease—IRS2—type 2 diabetes mellitus	2.93e-05	0.000662	CbGpPWpGaD
Framycetin—CXCR4—Disease—CALM1—type 2 diabetes mellitus	2.88e-05	0.00065	CbGpPWpGaD
Framycetin—CXCR4—Disease—APOE—type 2 diabetes mellitus	2.87e-05	0.000648	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.86e-05	0.000646	CbGpPWpGaD
Framycetin—CXCR4—Disease—APOA1—type 2 diabetes mellitus	2.83e-05	0.00064	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.81e-05	0.000634	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.8e-05	0.000634	CbGpPWpGaD
Framycetin—CXCR4—Disease—NOS2—type 2 diabetes mellitus	2.67e-05	0.000604	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.66e-05	0.0006	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.63e-05	0.000594	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AVP—type 2 diabetes mellitus	2.6e-05	0.000586	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.6e-05	0.000586	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.58e-05	0.000584	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.57e-05	0.000581	CbGpPWpGaD
Framycetin—CXCR4—Disease—IRS1—type 2 diabetes mellitus	2.56e-05	0.000578	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.55e-05	0.000575	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—APOB—type 2 diabetes mellitus	2.51e-05	0.000567	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.5e-05	0.000565	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.47e-05	0.000558	CbGpPWpGaD
Framycetin—CXCR4—Disease—INS—type 2 diabetes mellitus	2.45e-05	0.000553	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—LPL—type 2 diabetes mellitus	2.4e-05	0.000541	CbGpPWpGaD
Framycetin—CXCR4—Disease—AKT2—type 2 diabetes mellitus	2.37e-05	0.000535	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.34e-05	0.00053	CbGpPWpGaD
Framycetin—CXCR4—Disease—SERPINE1—type 2 diabetes mellitus	2.25e-05	0.000508	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.25e-05	0.000508	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.21e-05	0.000499	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—C3—type 2 diabetes mellitus	2.16e-05	0.000487	CbGpPWpGaD
Framycetin—CXCR4—Disease—NOS3—type 2 diabetes mellitus	2.15e-05	0.000485	CbGpPWpGaD
Framycetin—CXCR4—Disease—PIK3R1—type 2 diabetes mellitus	2.15e-05	0.000485	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.06e-05	0.000465	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.05e-05	0.000464	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AGT—type 2 diabetes mellitus	2.05e-05	0.000463	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.01e-05	0.000455	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—APOE—type 2 diabetes mellitus	2.01e-05	0.000454	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—LEP—type 2 diabetes mellitus	2.01e-05	0.000454	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.98e-05	0.000448	CbGpPWpGaD
Framycetin—CXCR4—Disease—PTGS2—type 2 diabetes mellitus	1.96e-05	0.000444	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.89e-05	0.000428	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.79e-05	0.000405	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—INS—type 2 diabetes mellitus	1.72e-05	0.000388	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.69e-05	0.000381	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.66e-05	0.000375	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.66e-05	0.000375	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.65e-05	0.000373	CbGpPWpGaD
Framycetin—CXCR4—Disease—SRC—type 2 diabetes mellitus	1.59e-05	0.000359	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.58e-05	0.000356	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.5e-05	0.00034	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.5e-05	0.00034	CbGpPWpGaD
Framycetin—CXCR4—Disease—TGFB1—type 2 diabetes mellitus	1.42e-05	0.000321	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—RELA—type 2 diabetes mellitus	1.42e-05	0.00032	CbGpPWpGaD
Framycetin—CXCR4—Disease—EGFR—type 2 diabetes mellitus	1.39e-05	0.000315	CbGpPWpGaD
Framycetin—CXCR4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.29e-05	0.000291	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.28e-05	0.000289	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.27e-05	0.000287	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.21e-05	0.000273	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.19e-05	0.00027	CbGpPWpGaD
Framycetin—CXCR4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.17e-05	0.000264	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SRC—type 2 diabetes mellitus	1.11e-05	0.000251	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.08e-05	0.000245	CbGpPWpGaD
Framycetin—CXCR4—Disease—IL6—type 2 diabetes mellitus	1.07e-05	0.000242	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.95e-06	0.000225	CbGpPWpGaD
Framycetin—CXCR4—Disease—AKT1—type 2 diabetes mellitus	9.87e-06	0.000223	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.75e-06	0.00022	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—IL6—type 2 diabetes mellitus	7.5e-06	0.000169	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.91e-06	0.000156	CbGpPWpGaD
